Answers are grounded in this paper and cite their sources.
Pilot study demonstrates a 50% resolution rate for oral leukoplakia with 5% imiquimod, indicating its potential as an effective noninvasive treatment option.
Background: Imiquimod (IMQ) is an immunomodulatory agent that possesses antitumor and antiviral activity with its proven effect on cancerous and precancerous lesions. It serves as a noninvasive treatment option for leukoplakia. Objective: To determine the effectiveness of 5% Topical IMQ in patients with oral homogeneous leukoplakia. Methods: This is an open-label, pilot study consisting of ten patients with clinically diagnosed oral homogeneous leukoplakia who were treated with 5% topical IMQ and were assessed clinically, followed by Visual Enhanced Light Scope examination pre- and posttreatment. Results: Complete resolution was noted in 50% of cases, and rest were left with a size less than 2 cm. Loss of fluorescence completely disappeared in all patient’s posttreatment, indicating the effectiveness of 5% IMQ cream in the management of oral leukoplakia (OL). Quantitative data were analyzed using the Wilcoxon signed-rank test. P < 0.005 and was considered statistically significant. Conclusion: IMQ shows promising results in managing OL and in reverting dysplastic changes. It also works as an alternative in cases unresponsive to conventional therapies.
No takes yet. Share an insight, caveat, or question.
Thorat et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: